TY - JOUR
T1 - The cell cycle inhibitor p27 is an independent prognostic marker in small (T(1a,b)) invasive breast carcinomas
AU - Tan, Puay
AU - Cady, Blake
AU - Wanner, Molly
AU - Worland, Peter
AU - Cukor, Barry
AU - Magi-Galluzzi, Cristina
AU - Lavin, Philip
AU - Draetta, Giulio
AU - Pagano, Michele
AU - Loda, Massimo
N1 - Copyright:
Copyright 2007 Elsevier B.V., All rights reserved.
PY - 1997
Y1 - 1997
N2 - Breast carcinomas ≤1 cm in size (T(1a,b)) are being detected more frequently as a result of screening. Because traditional prognostic parameters are either lacking (tumor size) or rare (nodal metastases), a marker(s) is needed to identify the subset of patients who could benefit from adjuvant therapy. A retrospective series of 202 patients with stage T(1a,b) invasive breast carcinomas was evaluated. The clinicopathological features (age, histological grade, extensive in situ carcinoma, hormone receptor status, and nodal metastasis) as well as microvessel density and the expression of c-erb-B2, p53, MIB-1/Ki-67, and cdc25B were assessed. In addition, expression of the cell cycle inhibitor p27 was evaluated. Nineteen patients (18% of patients who had axillary dissection) had locoregional lymph node metastases. Forty-two % of them died of disease (median survival, 112 months), whereas mortality was 11% in node-negative patients (median survival, 168 months; P = 0.0055). Patients with low p27 expression had a median survival of 139 months (17% mortality) versus 174 months (9% mortality) in the group with high p27 expression (P = 0.0233). Lack of p27 was associated with poor prognosis when node-positive patients were excluded (P = 0.0252). Nodal status and low p27 were found to be the only independent prognostic parameters by both univariate and multivariate analysis, with relative risks of dying of disease of 4.9 (P = 0.001) and 3.4 (P = 0.0306), respectively. Assessment of p27, which yields prognostic information in node- negative patients, could be useful to identify patients with small, invasive breast carcinomas who might benefit from adjuvant therapy.
AB - Breast carcinomas ≤1 cm in size (T(1a,b)) are being detected more frequently as a result of screening. Because traditional prognostic parameters are either lacking (tumor size) or rare (nodal metastases), a marker(s) is needed to identify the subset of patients who could benefit from adjuvant therapy. A retrospective series of 202 patients with stage T(1a,b) invasive breast carcinomas was evaluated. The clinicopathological features (age, histological grade, extensive in situ carcinoma, hormone receptor status, and nodal metastasis) as well as microvessel density and the expression of c-erb-B2, p53, MIB-1/Ki-67, and cdc25B were assessed. In addition, expression of the cell cycle inhibitor p27 was evaluated. Nineteen patients (18% of patients who had axillary dissection) had locoregional lymph node metastases. Forty-two % of them died of disease (median survival, 112 months), whereas mortality was 11% in node-negative patients (median survival, 168 months; P = 0.0055). Patients with low p27 expression had a median survival of 139 months (17% mortality) versus 174 months (9% mortality) in the group with high p27 expression (P = 0.0233). Lack of p27 was associated with poor prognosis when node-positive patients were excluded (P = 0.0252). Nodal status and low p27 were found to be the only independent prognostic parameters by both univariate and multivariate analysis, with relative risks of dying of disease of 4.9 (P = 0.001) and 3.4 (P = 0.0306), respectively. Assessment of p27, which yields prognostic information in node- negative patients, could be useful to identify patients with small, invasive breast carcinomas who might benefit from adjuvant therapy.
UR - http://www.scopus.com/inward/record.url?scp=0030894787&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030894787&partnerID=8YFLogxK
M3 - Article
C2 - 9102210
AN - SCOPUS:0030894787
SN - 0008-5472
VL - 57
SP - 1259
EP - 1263
JO - Cancer Research
JF - Cancer Research
IS - 7
ER -